Skip to main content

Table 2 Summary of Clinicopathological characteristics of the eligible studies

From: Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis

Study Patients factor Tumor factor AT, % Matched factora
No. of participants (female, %) Age, mean (SD), y Size, mean (SD), cm Site (head, %) VR, % CA19-9, mean (SD), U/ml
Barbier et al. [23] NAT: 88
SF:85
65 (39–81)g
64 (37–79)
NA 100
100
16
30
> 350 (16)b
> 350 (15)
0
NA
1, 4, 5, 6
Papalezova et al. [24] NAT: 144 (46)
SF: 92 (47)
64 (12)
65 (12)
2.5 (1.2)
2.1 (1.3)
100
100
18
22
NA 33
66
1, 2, 4, 5
Tajima et al. [25] NAT: 13 (46)
SF: 21 (33)
63 (51–77)g
66 (52–80)
NA 69
52
100
100
NA NA 1, 2, 4, 5
Cho et al. [26] NAT: 30 (47)
SF: 21 (52)
59.57 (8.6)
60.76 (10.8)
2.6 (0.9)
2.6 (0.8)
87
86
43
38
1189 (2482)
540 (840)
50
62
1, 2, 3, 4, 5, 6, 7
Jiang et al. [27] NAT: 112 (33)
SF: 120 (43)
45.9 (9.8)
45.5 (9.3)
NA 88
80
NA 211 (46)
284 (56)
0
0
1, 2, 4, 6, 7
Patel et al. [28] NAT: 17 (47)
SF: 13 (31)
60 (39–72)g
71 (42–82)
NA 88
85
NA NA 82
77
1, 2, 4, 7
Roland et al. [30] NAT: 222 (44)
SF: 85 (40)
64 (35–86)g
64 (40–85)
NA 92
87
31
27
< 1000 (74)b
< 1000 (66)
11
68
1, 2, 4, 5, 6
Lee et al. [29] NAT: 30 (60)
SF: 28 (50)
61.7 (8.8)
62.9 (9.6)
2.7(0.7)
2.6(0.7)
90
96
70
29
816 (1452)
504 (830)
73
75
1, 2, 3, 6, 7
Sho et al. [31]c NAT: 85 (45)
SF: 99 (47)
65.7 (8.9)
68.9 (10)
NA NA NA NA 61
48
2, 7
Golcher et al. [36] NAT: 33 (45)
SF: 33 (48)
62.5 (33–76)
65.1 (46–73)
NA 100
100
NA
22
NA 37
30
1, 2, 4, 7
Hirono et al. [32] NAT: 46
SF: 124
69 (41–90)g 3 (1.1–7.1)g
2.9 (1.2–8.5)
43
56
60
42
NA 53
64
3, 4, 5, 7
Masui et al. [33] NAT: 18 (56)
SF: 19 (68)
63 (43–73)g
66 (56–80)
3.3 (1.8–5)g
3.2 (1.7–7.5)
72
68
47
37
102
217
78
84
1, 2, 3, 4, 5, 6, 7
Ielpo et al. [3]d NAT: 45 (36)
SF: 36 (42)
62 (42–81)f
64 (46–78)
7.5
6.8
71
58
35
36
1754
1621
61
58
1, 2, 3, 4, 5, 6, 7
Murakami et al NAT: 52 (33)
SF: 25 (28)
> 67 (48)b
> 67 (60)
≥ 37 (52)b
≥ 37 (34)
67
84
62
57
> 150 (52)b
> 150 (52)
80
48
1, 2, 4, 6
Fujii et al. [34]e NAT: 40 (48)
SF: 233 (37)
65 (36–79)g
67 (35–88)
2.9 (1.5–5.2)g
2.5 (0.8–5.6)
100
100
25
32
143
148
67
66
1,2,3,4,5,6,7
NAT: 27 (56)
SF: 102 (48)
68 (47–78)g
66 (39–83)
3 (1.8–3.9)g
3.3 (1.5–7)
100
100
96
95
323
259
39
44
1, 2, 3, 4, 5, 6, 7
NAT: 21 (52)
SF: 81 (37)
68 (47–76)g
65 (42–82)
3.5 (2.6–4.6)g
3 (2–6)
100
100
79
87
286
218
46
43
1, 2, 3, 4, 5, 6, 7
Jang et al. [9] NAT: 27 (37)
SF: 23 (35)
59.4 (8.4)
58.9 (11.3)
3.4 (0.8)
3.5 (0.9)
85
74
35
28
1042 (2465)
1258 (2540)
52
57
1, 2, 3, 4, 5, 6, 7
Reni et al. [12] NAT: 32 (22)
SF: 26 (46)
64 (39–75)g
65 (37–74)
2.0 (0–6.0)g
2.5 (1.5–5.0)
88
96
0
9
173 (43–4510)
179 (39–3337)
72
65
1, 2, 3, 4, 5, 6, 7
  1. Abbreviations: NAT neoadjuvant therapy, SF surgery first, AT adjuvant therapy, VR vascular resection, NA not available
  2. aFactors matched with NAT and SF: 1, age; 2, sex; 3, initial tumor size; 4, tumor location; 5, vascular resection; 6, initial CA19-9 level; 7, AT
  3. bReported as range (percentage, %)
  4. cThe study by Sho et al. has 2 independent data sets (1 data set for RPC and 1 data set for BRPC)
  5. dThe study by lelpo et al. has 1 data set for RPC/BRPC, but it has 2 data subsets (1 data subset for RPC and 1 data subset for BRPC)
  6. eThe study by Fujii et al. has 3 independent data sets (1 data set for RPC, 1 data set for BRPC, and 1 data set for RPC/BRPC)
  7. fReported as mean (range)
  8. gReported as median (range)